公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2022 | Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals | Chen Y.-C.; Chang T.-S.; Chen C.-H.; Cheng P.-N.; Lo C.-C.; Mo L.-R.; Chen C.-T.; Huang C.-F.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Chen C.-Y.; Tseng K.-C.; Yu M.-L.; on behalf of TACR investigators | Viruses | 1 | 1 | |
2021 | Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan | Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; JIA-HORNG KAO ; Chuang W.-L.; Lin H.-C.; Yu M.-L. | Liver International | 25 | 23 | |
2016 | Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients | TUNG-HUNG SU ; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; SHIH-JER HSU ; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; TAI-CHUNG TSENG ; CHI-LING CHEN ; JIA-HORNG KAO ; the C-TEAM study group; the Taiwan Liver Diseases Consortium | Liver International | 165 | 149 | |
2016 | General and abdominal adiposity and risk of death in HBV versus non-HBV carriers: A 10-year population-based cohort study | Lin W.-Y.; Peng C.-Y.; Lin C.-C.; Davidson L.E.; Pi-Sunyer F.X.; Sung P.-K.; KUO-CHIN HUANG | Medicine (United States) | 4 | 5 | |
2011 | Genetic analysis of age-dependent defects of the Caenorhabditis elegans touch receptor neurons | C. L. Pan, C. Y. Peng, C. H. Chen and S. McIntire; Peng C.-Y.; CHUN-HAO CHEN | Proceedings of the National Academy of Sciences of the United States of America | 101 | 95 | |
2007 | Genistein induces apoptosis in human hepatocellular carcinomas via interaction of endoplasmic reticulum stress and mitochondrial insult | Yeh T.-C.; Chiang P.-C.; TSAI-KUN LI ; Hsu J.-L.; CHUN-JUNG LIN ; Wang S.-W.; Peng C.-Y.; JIH-HWA GUH | Biochemical Pharmacology | 123 | 110 | |
2020 | Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment | CHEN-HUA LIU ; Yang S.-S.; Peng C.-Y.; Lin W.-T.; CHUN-JEN LIU ; TUNG-HUNG SU ; TAI-CHUNG TSENG ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Journal of Viral Hepatitis | 20 | 20 | |
2015 | HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients | Peng C.-Y.; Hsieh T.-C.; Hsieh T.-Y.; Tseng K.-C.; Lin C.-L.; TUNG-HUNG SU ; TAI-CHUNG TSENG ; Lin H.H.; Wang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 12 | 11 | |
2009 | Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: A randomized phase II trial for safety and optimal dosage | CHUN-JEN LIU ; PO-HUANG LEE ; Lin D.-Y.; Wu C.-C.; Jeng L.-B.; Lin P.-W.; Mok K.-T.; Lee W.-C.; Yeh H.-Z.; MING-CHIH HO ; Yang S.-S.; Lee C.-C.; Yu M.-C.; REY-HENG HU ; Peng C.-Y.; Lai K.-L.; Chang S.S.-C.; PEI-JER CHEN | Journal of Hepatology | 131 | 125 | |
2021 | Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort) | Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. | Journal of Gastroenterology and Hepatology (Australia) | 7 | 10 | |
2014 | Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B | Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO ; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L. | Journal of Gastroenterology and Hepatology (Australia) | 9 | 8 | |
2022 | The impact of body mass index on clinicopathological features of nonalcoholic fatty liver disease in Taiwan | Lin C.-L.; Tai C.-M.; Huang J.-F.; CHUN-JEN LIU ; Chen H.-F.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Wang C.-C.; Weng S.-H.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 2 | 2 | |
2022 | Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR) | Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; SHIH-JER HSU ; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. | Clinical Gastroenterology and Hepatology | 14 | 12 | |
2004 | The indazole derivative YD-3 inhibits thrombin-induced vascular smooth muscle cell proliferation and attenuates intimal thickening after balloon injury | Peng C.-Y.; Pan S.-L.; JIH-HWA GUH ; Liu Y.-N.; Chang Y.-L.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Thrombosis and Haemostasis | 21 | 21 | |
2010 | The indazole derivative YD-3 specifically inhibits thrombin-induced angiogenesis in vitro and in vivo | Peng C.-Y.; Pan S.-L.; Pai H.-C.; Tsai A.-C.; JIH-HWA GUH ; Chang Y.-L.; Kuo S.-C.; Lee F.-Y.; Teng C.-M. | Shock | 5 | 5 | |
2016 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus | Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 20 | |
2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
2022 | Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan | Lo C.-C.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Chen C.-Y.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; CHEN-HUA LIU ; Lee M.-H.; CHUN-JEN LIU ; Dai C.-Y.; Chuang W.-L.; Lin H.-C.; JIA-HORNG KAO ; Yu M.-L.; TACR investigators | Journal of the Formosan Medical Association | 3 | 0 | |
2021 | Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH) | Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; JIA-HORNG KAO ; CHEN-HUA LIU ; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU ; Yu M.-L. | Hepatology International | 4 | 5 | |
2021 | Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan | Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; JIA-HORNG KAO ; CHUN-JEN LIU ; CHEN-HUA LIU ; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators | Journal of Gastroenterology and Hepatology (Australia) | 2 | 3 |